Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/05 → 1/31/12 |
A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclosphamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck
- Kenady, Daniel (PI)